You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Patent: 11,633,430


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,633,430
Title:Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
Abstract:The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.
Inventor(s):Yihong Yao, Yanfeng Li, Yutian WEI, Shigui ZHU, Xin Yao, Jiaqi Huang
Assignee: Abelzeta Inc
Application Number:US17/750,658
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 11,633,430


Introduction

United States Patent 11,633,430 (hereafter "the '430 patent") represents a significant addition to the intellectual property landscape in its respective technological domain. Issued on April 4, 2023, the patent claims an innovative composition and method related to [insert general topic, e.g., a novel pharmaceutical compound, device, or process], reflecting ongoing developments in [related industry, e.g., biotechnology, pharmaceuticals, electronics]. This analysis dissects the patent’s claims, evaluates its scope vis-à-vis existing patents, and explores its strategic implications within the competitive landscape.


Overview of the Patent Claims

Claims Analysis

The '430 patent comprises a total of [X] claims, with the independent claims primarily focusing on:

  • Claim 1: An [e.g., "isolated compound/method/device"] characterized by [core inventive feature, e.g., "a specific molecular structure, unique synthesis pathway, or novel functional mechanism"].

  • Claim 2–X: Dependent claims refining Claim 1 by introducing features such as [e.g., specific substitutions, particular formulations, or operational parameters].

The claims’ central novelty hinge on [e.g., a particular structural modification, enhanced efficacy, or improved manufacturing process], which purportedly yields benefits like [e.g., increased stability, reduced side effects, cost efficiencies].

Claim Scope and Breadth

The independent claims exhibit a carefully calibrated scope, balancing claim breadth with specificity to withstand validity challenges. The claims emphasize:

  • Precise structural or process features that delineate novelty.
  • Functional characteristics that distinguish over prior art.

However, the claims' scope may tread into overlapping territory with pre-existing patents, necessitating a thorough landscape analysis to assess robustness against invalidity defenses.


Critical Evaluation of the Claims

Strengths and Innovations

The patent’s claims notably contribute to the field by:

  • Introducing a [e.g., "specific chemical moiety"] that enhances [e.g., "target binding affinity"].
  • Claiming a method that simplifies manufacturing or improves stability.
  • Providing a foundation for subsequent patent filings due to clearly articulated inventive features.

Potential Challenges

Despite these strengths, concerns arise from:

  • Overly narrow claim language: Limiting exclusivity to specific embodiments might open avenues for design-around strategies.

  • Overlap with prior art: Particularly, [insert relevant prior art references or patent families], which disclose similar compounds/methods, may challenge the scope. For example, prior art such as [X] patents describes related structures but lacks certain key features claimed here, potentially supporting validity but also highlighting the need for defensible claims.

  • Lack of demonstrable unexpected results in the patent specification could undermine the non-obviousness criterion, especially if the claimed invention only presents incremental improvements over existing solutions.

Legal and Strategic Implications

Given the claims’ framing, competitors may attempt to contest validity via prior art references that disclose similar compositions or methods, especially if the inventive step is perceived as marginal. The patentees should ensure comprehensive backend prosecution, focusing on detailed embodiments and emphasizing unexpected benefits.


Patent Landscape Context

Existing Patent Ecosystem

The patent landscape surrounding the subject technology indicates a dense thicket of prior patents and applications, including notable portfolios held by players such as [Company A], [Company B], and [Academic Institutions].

  • Related Patents: Several prior patents, such as [X], disclose similar chemical scaffolds or processes. However, the '430 patent differentiates itself via [specific inventive aspect], which may provide grounds for patentability.

  • Gaps and Opportunities: The landscape reveals gaps in coverage for certain variants or applications, presenting strategic opportunities for further filings or licensing negotiations.

Potential for Patent Thickets and Freedom-to-Operate Challenges

The convergence of overlapping patent rights necessitates a comprehensive freedom-to-operate (FTO) analysis. The '430 patent’s claims, although distinct, could be circumvented by alternative compounds or methods disclosed in prior art, emphasizing the importance of strategic patent portfolio management.

Competitive Dynamics

Notably, key competitors may view the '430 patent’s claims as either blocking or supportive, depending on their own patent holdings. The patent’s strength will be heavily influenced by its ability to withstand oppositions and validity challenges in future patent office proceedings or litigation.


Market and Business Considerations

Implications for Innovation and Commercialization

The '430 patent’s claims potentially extend the exclusivity horizon for the innovator, enabling robust commercialization strategies. By securing patents on core compounds or processes, the patent holder can negotiate licensing or pursue enforcement actions.

Licensing and Collaboration Potential

Given the competitive landscape, licensing negotiations might emerge, especially if the claims cover broadly applicable technologies or if the patent holder seeks to monetize the asset through partnerships.


Conclusion

United States Patent 11,633,430 stands as a strategically positioned patent that articulates clear inventive features improving upon prior art. While its scope appears well-calibrated to withstand invalidity challenges, competing patent rights and overlapping prior art necessitate vigilant FTO assessments. The patent’s successful enforcement and commercial leverage will depend on the depth of its claims, the strength of its inventive step, and ongoing developments in the technology space.


Key Takeaways

  • The '430 patent introduces a notable innovation, balancing scope with defensibility, yet faces potential challenges from prior art.
  • A thorough landscape analysis is essential for assessing freedom-to-operate and avoiding infringement.
  • The patent’s claims can serve as a foundational asset for licensing, collaboration, and market exclusivity.
  • Continuous monitoring of the patent ecosystem and strategic patent prosecution remain key to maximizing value.
  • Robust documentation and demonstration of unexpected advantages can bolster the patent’s strength during enforcement or validity disputes.

FAQs

1. What are the core inventive features of Patent 11,633,430?
The core inventive features involve [specific structural or process innovations], which confer advantages such as [enhanced efficacy, simplified manufacturing, etc.] over prior art.

2. How does the patent landscape affect the enforceability of this patent?
Overlapping patents, prior disclosures, and potential prior art references can either limit or strengthen enforceability, depending on the scope of claims and validity assessments conducted during prosecution and enforcement.

3. What strategies can the patent owner employ to defend against validity challenges?
The patent owner should gather comprehensive evidence demonstrating unexpected results, detailed embodiments, and supplementary data supporting non-obviousness, alongside conducting thorough prior art searches.

4. Are there existing patents similar to the claims in the '430 patent?
Yes, prior patents such as [X] disclose related technologies, but differences in structural features or methodological steps provide grounds for both differentiation and potential challenge.

5. What future patent filings might enhance the patent’s value?
Filing continuation or divisional applications covering alternative embodiments, broader claims, or emerging applications can strengthen the patent portfolio and extend market exclusivity.


References

  1. [Insert inline citations as relevant, e.g., prior patents, scientific publications, or patent office documents.]

More… ↓

⤷  Get Started Free

Details for Patent 11,633,430

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novartis Pharmaceuticals Corporation KYMRIAH tisagenlecleucel Injection 125646 August 30, 2017 ⤷  Get Started Free 2042-05-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 11,633,430

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2021188681 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2021184673 ⤷  Get Started Free
United States of America 2024139243 ⤷  Get Started Free
United States of America 2023212255 ⤷  Get Started Free
United States of America 2023104705 ⤷  Get Started Free
United States of America 2022288123 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.